Clinical Trials | August 26, 2024
Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
The robotic surgery program has continually pushed the boundaries of medical technology
Becomes the first rehab & recovery center in east India to earn NABH accreditation
Subscribe To Our Newsletter & Stay Updated
